LP-195 Design of a Phase 2 study evaluating the efficacy and safety of nipocalimab in adult patients...
LP-195 Design of a Phase 2 study evaluating the efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
BackgroundSystemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease characterized by pathogenic autoantibodies and tissue damage to multiple organ systems. Nipocalimab is a novel high affinity, fully human, aglycosylated, effectorless IgG1 monoclonal antibody that selectively blocks the neonatal Fc receptor (FcRn). Nipocalimab has...
Alternative Titles
Full title
LP-195 Design of a Phase 2 study evaluating the efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c6e997afdef64c1da2cbc99768b4e302
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c6e997afdef64c1da2cbc99768b4e302
Other Identifiers
E-ISSN
2053-8790
DOI
10.1136/lupus-2023-KCR.267
